Black Hawk Acquisition holds extraordinary general meeting; 77.3% of shares represented

Black Hawk Acquisition Corporation held an extraordinary general meeting on October 13, 2026. Shareholders authorized the business combination agreement with Vesicor Therapeutics and BH Merger Sub, covering the related transactions. Investors also backed a domestication to Delaware; the vote did not confirm completion of the move. Approval was granted to adopt a new certificate of incorporation and bylaws, effective upon the domestication. Shareholders also voted to select five directors to serve following the business combination. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Hawk Acquisition Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-011077), on October 13, 2026, and is solely responsible for the information contained therein. (C) Co